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Abstract
Background: Circulating CD34
+ cells, a population that includes endothelial progenitors, participate in the maintenance of
endothelial integrity. Better understanding of the mechanisms that regulate their survival is crucial to improve their
regenerative activity in cardiovascular and renal diseases. Chemokine-receptor cross talk is critical in regulating cell
homeostasis. We hypothesized that cell surface expression of the chemokine fractalkine (FKN) could target progenitor cell
injury by Natural Killer (NK) cells, thereby limiting their availability for vascular repair.
Methodology/Principal Findings: We show that CD34
+-derived Endothelial Colony Forming Cells (ECFC) can express FKN in
response to TNF-a and IFN-c inflammatory cytokines and that FKN expression by ECFC stimulates NK cell adhesion, NK cell-
mediated ECFC lysis and microparticles release in vitro. The specific involvement of membrane FKN in these processes was
demonstrated using FKN-transfected ECFC and anti-FKN blocking antibody. FKN expression was also evidenced on
circulating CD34
+ progenitor cells and was detected at higher frequency in kidney transplant recipients, when compared to
healthy controls. The proportion of CD34
+ cells expressing FKN was identified as an independent variable inversely
correlated to CD34
+ progenitor cell count. We further showed that treatment of CD34
+ circulating cells isolated from adult
blood donors with transplant serum or TNF-a/IFN-c can induce FKN expression.
Conclusions: Our data highlights a novel mechanism by which FKN expression on CD34
+ progenitor cells may target their
NK cell mediated killing and participate to their immune depletion in transplant recipients. Considering the numerous
diseased contexts shown to promote FKN expression, our data identify FKN as a hallmark of altered progenitor cell
homeostasis with potential implications in better evaluation of vascular repair in patients.
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Introduction
Endothelium dysfunction plays a central role in the pathogen-
esis of vascular disorders. During the past decade, evidence has
accumulated to show how endothelial integrity results from a
critical balance between damage and repair processes. Repair of
injured endothelium does not solely depend on vessel wall
endothelial cells but also on circulating progenitors originating
from the bone marrow or other niches[1]. The CD34
+ pool of
circulating cells encompasses a widely heterogeneous cell popula-
tion comprising mainly progenitors of hematopoietic lineage
paracrinally active in the promotion of endothelial repair, and a
scarce fraction of endothelial progenitor cells (EPC) referred as
endothelial colony forming cells (ECFC)[2]. EPC have the specific
ability to differentiate into endothelial cells and integrate into
damaged endothelial layer but also play major role in new vessel
formation [3–5].
Accumulating evidence indicates that EPC constitute interest-
ing targets for regeneration in cardiovascular and renal disease
[6]. Altered EPC numbers and function have been described in
patients with renal failure [7–9]. This defect could contribute to
accelerated arteriosclerosis and high cardiovascular morbidity
observed in chronic kidney disease. In the transplantation setting,
it was also demonstrated that these progenitor cells have a
potential to migrate in human allografts, replace damaged donor
endothelium and limit alloimmune injury of graft endothelium
[10,11].
Reduced number and activity of CD34
+ progenitors are
expected to constitute a hallmark of vascular disease progression
and transplant damage [12,13].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26663Investigation of the role of the chemokine-receptor cross talk in
regulating progenitor dependent repair processes has open
therapeutic perspectives to favor CD34
+ regenerative functions
as exemplified by studies mainly focused on SDF1-CXCR4
interactions [14,15].
Fractalkine (FKN) is a membrane-bound chemokine expressed
mainly by activated endothelial cells [16,17] and interacts with its
cognate receptor CX3CR1, expressed predominantly on innate
immune Natural Killer (NK) cells [18]. FKN induction on mature
endothelial cells was shown to enhance NK-cell cytotoxic [19] and
proinflammatory cytokine production [20].
The recognition of inhibitory and activating target cell ligands by
a wide repertoire of NK cell receptors controls the efficiency of host
innate immune responses to neoplastic, infectious and allogeneic
challenges [21]. Through sensing of a variety of constitutive or
stress-induced ligands on target cells, NK cells act as early cytotoxic
effector cells towards recognized targets. While the allogeneic
potential of NK cells was mostly investigated in bone marrow
transplantation, growing evidence suggests that NK cells may also
participate to vascular injury in various pathological settings
including atherosclerosis and solid organ rejection [22–25].
The FKN/CX3CR1 axis has been involved in the pathogenesis
of numerous disorders including atherosclerosis, vasculitis, renal
disease and kidney allograft rejection [17,26]. In addition,
CX3CR1 targeted deletion or inhibition of the FKN-CX3CR1
pathway has been reported to prolong survival of cardiac allografts
[27,28].
However, the mechanisms that sustain the role of NK cells in
the control of vascular integrity remain poorly addressed and the
specific implication of the FKN/CX3CR1 pathway in progenitor
cell homeostasis has never been investigated.
We hypothesize that sensing of stress-induced FKN on EPC by
innate NK cells could target progenitor cell depletion.
Therefore, we first investigated whether FKN expression can be
induced on CD34
+-derived Endothelial Colony Forming Cells
(ECFC) upon inflammatory stimuli. We further evaluated whether
up regulation of membrane FKN can activate NK cell adhesion
and cytotoxic activity towards progenitor cells in vitro. We then
investigated whether FKN expression can also be observed on
circulating CD34
+ cells in vivo and be associated with lowered
progenitor cell count in a cohort of kidney transplant recipients.
Finally, we evaluated if serum from transplant recipients and
inflammatory cytokines TNF-a and IFN-c can induce FKN
expression on circulating CD34
+ progenitors isolated from healthy
subjects.
Results
Inflammatory cytokines induce Fractalkine expression in
CD34
+-derived ECFC
We first investigated whether FKN expression may be induced
on CD34
+-derived endothelial colony forming cells (ECFC) after
treatment with inflammatory cytokines TNF-a and IFN-c.
While no baseline FKN expression was detected in resting
endothelial and progenitor cells, TNF-a and IFN-c induced FKN
mRNA (Fig. 1A) but also FKN cell surface expression on CD34
+-
derived endothelial colony forming cells, as detected by flow
cytometry (Fig. 1B). FKN expression was similarly induced on
stimulated glomerular endothelial HGMEC cells used as positive
controls. Induction of membrane FKN was consistently observed
using distinct batches of ECFC (n=6) and HGMEC (n=5). FKN
expression on ECFC was confirmed by immunofluorescence
microscopy (Fig. 1C), using co-staining with CD31 antibody used
to attest the endothelial differentiation of CD34
+-derived progenitors.
Fractalkine expression by ECFC enhances NK cell
adhesion
We then investigated the impact of membrane FKN expression
in NK cell adhesion to ECFC. As TNF-a/IFN-c stimulation up-
regulated adhesion molecules involved in immune cell adhesion
like ICAM-1, VCAM-1, HLA class I (data not shown), the specific
involvement of FKN in NK cell adhesion was investigated using
membrane FKN-transfected ECFC and purified NK cells. FKN
transfection resulted in cell surface expression in 50% of CD34
+-
derived ECFC (Fig. 2A) and led to an increase in NK cell adhesion
(Fig. 2B), when compared to adhesion of NK cells to control
vector-transfected ECFC. The involvement of FKN in NK cell
adhesion to ECFC was further analyzed by confocal microscopy
(Fig.2C, left panel). ECFC were transfected with pIRES2
expression vector encoding both membrane FKN and GFP and
incubated with purified NK cells labeled with DiD membrane dye.
The specific involvement of FKN in NK cell adhesion was
confirmed by preincubation of FKN-GFP ECFC with anti-FKN
neutralizing antibody that resulted in a 50% reduction of the
number of NK cells adherent to FKN-transfected ECFC (Fig. 2C,
right panel).
Fractalkine expression by ECFC enhances their lysis by NK
cells
We further investigated whether membrane FKN expression
can enhance cytotoxic activity of immune cells towards ECFC and
limit progenitor cell survival. We show that membrane FKN
transfection renders CD34
+-derived endothelial progenitors more
susceptible to lysis by PBMC effector cells when compared with
control vector-transfected ECFC, resulting in a mean 7 fold
induction of ECFC cell death (Fig. 3A and 3B). This effect was
consistent in independent assays performed in triplicate using
PBMC isolated from seven distinct blood donors as effectors and
transiently FKN- or control vector- transfected ECFC as targets.
When purified NK cells were added as effector cells, we
observed a 4 fold induction of FKN-transfected ECFC lysis when
compared to control vector transfected ECFC (Fig. 3C). In
addition, preincubation of FKN-transfected ECFC with anti-FKN
neutralizing antibody protected ECFC from NK lysis (Fig. 3D).
Consistent with FKN-mediated ECFC damage, incubation of
FKN-transfected ECFC with PBMC during 24 hours resulted in
enhanced microparticles release by FKN-transfected ECFC
compared to control vector-transfected ECFC (Fig. 3E).
The CD34
+ circulating progenitor cell subset expressing
FKN is increased in kidney transplant patients and
constitutes an independent factor correlating to lowered
CD34
+ progenitor cell count
As CD34
+ circulating progenitor cells are the precursors that
give rise to ECFC, we further aimed to determine if FKN
expression could also be expressed on circulating CD34
+
progenitor cells in vivo. We therefore conducted a flow cytometry
analysis of circulating CD34
+ and CD34
+FKN
+ subsets in a cohort
of 168 kidney-transplant recipients (KTR) evaluated at a median
of 5.8 years post transplant that allowed detection of FKN
expression in a fraction of circulating CD34
+ cells. The % of
CD34
+ cells expressing FKN (Fig. 4A) and the frequency of
CD34
+FKN
+ subset was significantly higher in KTR than in
gender and age-matched controls (x
2,p ,0.0001). We then
investigated whether FKN expression was associated to a decrease
in CD34
+ progenitors in patients. Individuals with low CD34
+
counts (threshold cutoff value set at 2800 CD34
+ cells/ml, the 25
lower percentile of CD34
+ count observed in controls) were more
Fractalkine Targets Progenitor Cell Lysis
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26663Figure 1. FKN expression is induced in CD34
+-derived ECFC by inflammatory cytokines. (A) Quantitative RT-PCR analysis and (B)
Representative flow cytometry histograms showing FKN expression in ECFC (n=6) and HGMEC (n=5) in response to TNF-a and IFN-c.( C) FKN
expression by TNF-a + IFN-c stimulated ECFC was also assessed by immunofluorescence microscopy, using a goat anti-FKN Ab and revealed by an
Alexa 488-conjugated donkey anti-goat Ab. CD31 expression was detected using a mouse anti-CD31 Ab and revealed by an Alexa 546-conjugated
goat anti-mouse Ab. The nuclei were stained with Dapi.
doi:10.1371/journal.pone.0026663.g001
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and age matched control group (23%; x
2, p=0.028) (Fig. 4B).
Consistently, patients with low CD34
+ levels (,2800 cells/ml)
exhibited higher % of FKN expression on CD34
+ progenitors than
KTR with CD34
+ levels .2800 cells/ml (p=0.0072).
Multivariate analysis showed that % CD34
+FKN
+, age and
acute rejection history were independent factors associated with
CD34
+ cell count in transplanted patients (Table 1).
KTR serum and inflammatory cytokines induce FKN
expression on CD34
+ circulating progenitor cells
We further investigated whether soluble factors present in
transplant sera from patients with high % of CD34
+FKN
+ can
induce FKN expression on CD34
+ progenitor cells freshly isolated
from control donors. We show that FKN induction was not
restricted to in vitro CD34
+-derived endothelial cell progenitors but
was also inducible on CD34
+ circulating cells. Indeed, flow
cytometry analysis showed that serum from KTR (Fig.5A and 5C)
but also TNF-a/IFN-c (Fig. 5B) induced FKN expression on
CD34
+ progenitors gated within PBMC (Fig. 5B) or within
CD133
+ purified progenitor cells (Fig. 5C), while serum collected
from CD34
+ FKN negative healthy donors or control medium did
not induce FKN expression (Fig. 5).
Discussion
Our study unravels a novel mechanism by which Immune NK
cells may control endothelial and hematological progenitor cell
homeostasis. We show that FKN expression by endothelial
progenitor cells leads to their NK mediated-killing in vitro and
associates to a reduced number of CD34
+ cells in vivo.
This work is the first to show that membrane fractalkine
expression can be induced on both circulating CD34
+ cells and
CD34
+-derived endothelial progenitor cells. In CD34
+-derived
endothelial progenitor cells with no baseline FKN expression, we
show that TNF-a and IFN-c induce transcriptional and cell
surface expression of FKN. We confirmed that such up-regulation
was not limited to in vitro cultured cells, but could also be observed
on purified progenitor cells freshly isolated from healthy adult
blood donors upon treatment with serum of KTR patients or
TNF-a/IFN-c.
Previous studies have indeed shown that membrane FKN
expression can be induced on mature endothelial cells by
proinflammatory cytokines [16,19]. In line with these data we
show that glomerular microvascular endothelial cells, regarded as
a major target of immune injury during allograft rejection [29] can
also express fractalkine in response to inflammatory stimuli.
Through interaction with its cognate receptor CX3CR1, fractalk-
ine expression by endothelial cells was reported to mediate their
NK-mediated lysis and also to stimulate interferon-gamma
production by innate NK cells [19,20]. Enhanced FKN and
CX3CR1 expression have also been detected in rejected
transplant biopsies and associated with cardiovascular disorders,
renal inflammation and fibrosis [17,26,30–32].
Our work thus brings the first evidence that FKN expression is
not only a feature of mature cell activation, but may also constitute
a signal modulating immune functions toward CD34
+-derived
endothelial progenitors, when these cells are submitted to
inflammatory stimuli.
Altogether, these observations led to the hypothesis that FKN up
regulation can stimulate cytotoxic NK cell functions towards
progenitors and constitute a mechanism affecting their homeostasis.
To sustain this hypothesis, we showed that FKN up regulation
on ECFC constitutes a ‘‘danger’’ signal that enhances both NK
cell adhesion and cytotoxicity towards ECFC. The specific
implication of membrane FKN in targeting NK cell adhesion and
NK-mediated ECFC cell death was assessed using FKN-
transfected ECFC and anti-FKN blocking antibody. We also
provide evidence that FKN mediated ECFC lysis resulted in
enhanced ECFC-derived microparticles release. Such micropar-
ticles release by apoptotic or activated endothelial cells has been
reported as a signature of endothelial injury in various
cardiovascular and renal diseases but also as vehicles of
coagulation, inflammation, endothelial function and ECFC
dependent vascular homeostasis [33,34]. Altogether, we show
that FKN-mediated activation of NK cell cytotoxicity towards
ECFC can bypass autologous or allogeneic inhibitory signals
delivered to NK cells.
The in vivo relevance of FKN expression by CD34
+ circulating
cells and its potential implications in progenitor cell homeostasis
was provided in the context of kidney transplant. Detection of
CD34
+ subset expressing high FKN levels was significantly more
frequent in transplanted recipients, and rarely observed in healthy
blood donors. Moreover, we provide evidence that %CD34
+FKN
+
is an independent factor inversely associated with CD34
+ cell
count in a representative cohort of transplant recipients, thus
supporting the view that FKN expression may constitute a specific
phenotypic feature of CD34
+ cells in patients with lowered
progenitor cell number.
The specific factors that contribute to FKN expression in kidney
transplant recipients remain to be characterized. FKN up
regulation could be the consequence of inflammation associated
with alloimmune conflict and kidney dysfunction.
Indeed serum levels of inflammatory cytokines such as TNF-a
were described to be higher in kidney transplant patients and
increased significantly during allograft rejection [35]. Sera of
patients that exhibit high % of blood CD34
+FKN
+ induced FKN
expression in circulating CD34
+ isolated from healthy donors with
no baseline FKN expression. This suggests that soluble factors
participate to FKN up-regulation in transplanted patients.
Several studies have identified exhaustion of CD34
+ circulating
progenitor cells as a surrogate marker predicting vascular
dysfunction, cumulative CV risk and graft vasculopathy [13,36–
38]. Definition of mechanisms and markers that characterize the
fate of circulating progenitor cells are crucial issues to optimize the
prognosis of vascular diseases. There is growing evidence to show
that FKN may be involved in atherosclerosis and cardiovascular
disease progression [17,26] but activation of this pathway has
Figure 2. FKN expression by CD34
+-derived ECFC enhances NK cell adhesion. (A) Flow cytometry analysis of FKN expression by ECFC 24 h
after transfection with pCDNA3.1 vector encoding membrane FKN. (B) FKN- and control empty vector-transfected cells were incubated for 1 h with
CMFDA labeled NK cells at an effector: target ratio of 1:1. (B, left panel): NK cell adhesion was analyzed by epi-fluorescence microscopy on an
inverted microscope Nikon TE2000-U with a Plan Fluor 4x/0.13 objective. (B, right panel): The number of ECFC-adherent NK cells/field was assessed
using Image J 1.43 software cell counter. (C) Interactions between FKN transfected ECFC and NK cells were detected by confocal microscopy. (C, left
panel) ECFC transfected with pIRES2-EGFP vector encoding membrane FKN (shown in red) were incubated for 1 h with DiD labelled purified NK cells
at an effector: target ratio of 1:1 (shown in green). (C, right panel): FKN-transfected ECFC were treated with 30 mg/ml of anti-human FKN antibody
prior incubation with NK cells. The number of ECFC adherent NK cells was assessed by counting DiD positive NK cells/field, using Image J 1.43
software cell counter.
doi:10.1371/journal.pone.0026663.g002
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cell number. As the FKN-CX3CR1 axis has also been implicated
in atherosclerosis progression [17,39], we expect that FKN-
mediated NK cell activation may impair host capacity to
counteract onset of atherosclerosis. In the context of kidney
transplant, NK cells may thus exert dual deleterious effector
function, not only by promoting allogeneic endothelial cell lesion,
but also by limiting recipient progenitor cell availability to repair
graft and systemic vascular lesions. Monitoring of blood subsets
that sign immune tolerance is a challenge to adapt conditioning
and immunosuppressive treatment in the clinical setting of
hematopoietic and organ transplant. Evaluation of the circulating
CD34
+ compartment may also be of interest in the context of
kidney transplant follow-up, notably in novel therapeutic ap-
proaches when combined donor hematopoietic stem cell and
kidney transplantation are indicated to favor better graft tolerance
and immunosuppressive drug withdrawal [40,41].
Our study highlights the potential value of CD34
+FKN
+ as a
marker that refines evaluation of the progenitor cell compartment
and prompts future prospective studies exploring if evaluation of
the circulating CD34
+FKN
+ subset can identify patients with
lower repair potential and at higher risk to develop CV diseases or
renal transplant dysfunction.
In summary, our data support a role for FKN as a gatekeeper
controlling immune NK cell activation towards CD34
+ and
endothelial progenitor cells. In response to various pathogenic
challenges, NK cells may thus behave as early immune effectors
limiting availability of progenitor cells competent for vascular
repair. Better understanding of FKN/CX3CR1 dependent
mechanisms that render CD34
+ progenitor cells immunogenic
may be of interest to favor stem cell mediated regeneration in
various diseases and may contribute to design therapies interfering
with the FKN-CX3CR1 pathway to improve graft survival and
limit cardiovascular disorders.
Methods
Cells and cell culture
Endothelial Colony Forming Cells (ECFC) were generated after
density-gradient isolation of human cord blood or peripheral
blood mononuclear cells and CD34
+ cells were purified by
magnetic cell separation using the CD34 progenitor-cell isolation
kit (Miltenyi Biotech Bergisch-Gladbach, Germany). Cells were
plated on 24-wells culture dishes coated with gelatin 0,2 % (Sigma,
Saint-Quentin Fallavier) and cultured in endothelial basal medium
EBM-2 (Lonza, Saint Bauzire, France) supplemented with 2%
fetal bovine serum and an endothelial growth supplement (EGM-2
SingleQuots, Lonza). The medium was replaced every 3 days until
the appearance of ECFC colonies. Flow cytometry (flow
cytometry) analysis of ECFC showed that these cells express
Figure 3. Membrane FKN targets CD34
+-derived ECFC lysis by NK cells. (A) Cytotoxicity assay performed using PBMC effector cells isolated
from 7 independent blood donors as described in Methods. Each independent assay was performed in triplicate (n=7) and analysed using an
effector: target ratio=100:1. (B) Representative illustration of ECFC lysis. CMFDA labeled target cells were analyzed by epi-fluorescence microscopy
on an inverted microscope Nikon Eclipse TE 2000-U with a Plan Fluor 4x /0.13 objective, images were acquired using NIS elements AR software. (C)
FKN enhances ECFC lysis by purified NK cells. CMFDA cytotoxicity assay performed using purified NK cells as effectors, effector: target ratio=10:1,
(n=3). (D) Addition of FKN neutralizing antibody reduces ECFC lysis. FKN-transfected ECFC were treated with 30 mg/ml of anti-human FKN antibody
before addition of PBMC (n=3). (E) Lysis of FKN expressing ECFC resulted in increased microparticles release after 24 h of incubation with PBMC.ECFC
were labeled with the lipophilic DiD tracer and transfected with pCDNA3.1 vector coding for membrane FKN (grey bars) or with pCDNA 3.1 empty
vector (white bars) and cultured for 24 h. PBMC were added at an effector: target ratio of 50:1 and co-cultured with target cells for 4 h and 24 h,
(n=5). DiD positive microparticles released by target cells were enumerated by calculation of MP=ml~MP targetszeffectors ðÞ {MPtargets:
doi:10.1371/journal.pone.0026663.g003
Figure 4. CD34
+ progenitors expressing FKN are found at higher occurrence in transplant recipients analyzed in reference to
gender and matched controls. (A) % of CD34
+ progenitors expressing FKN were evaluated by flow cytometry, in 168 kidney transplant recipients
(KTR), and a subgroup of 58 KTR was also analyzed in reference to a gender- and age- matched healthy control group (CTL). (B) The % of individuals
exhibiting low CD34
+ cell count is higher in the group of transplant recipients, when analyzed in reference to a group of gender and age-matched
controls (n=58). The 2800 cells/ml cut off value for CD34
+ cells corresponding to the 25 percentile observed in controls was used as a threshold of
low CD34
+ cell count.
doi:10.1371/journal.pone.0026663.g004
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CD31.
Human glomerular microvascular endothelial cells (HGMEC)
were purchased from Cell Systems (Kirkland, WA, USA) and
grown according to the manufacturer’s instructions.
Purified NK cells were isolated by negative selection using
StemSepH Human NK Cell Enrichment Cocktail (StemCell
Technologies, Grenoble, France). The purity of CD3
- CD56
+
NK cells was .85% as assessed by flow cytometry.
Quantitative RT-PCR analysis
Total RNA was extracted from ECFC and HGMEC using the
RNA extraction kit (Qiagen, Courtaboeuf, France) and 3 mgo f
RNA was reverse-transcribed to cDNA according to the
manufacturer’s instructions, using random hexamers (Invitrogen).
cDNA was analyzed for expression of FKN/CX3CL1 transcript by
real time PCR using FastStart DNA Master
PLUSSybrGreen I
reaction Mix on a Light CyclerH 480 (Roche Applied Science,
Meylan, France). The expression of FKN transcript was normal-
ized to the expression of the housekeeping gene HPRT. The
sequences of oligonucleotide primers used for CX3CL1 and HPRT
amplification were: CX3CL1forward: 59-ACGAAATGCAACAT-
CACGTGC-39; CX3CL1reverse: 59-TCCAAGATGATTGC-
GCGTT-39; HPRTforward: 59-GAGCTATTGTAATGACCAG-
TCAACAGGG-39; HPRTreverse: 59- GGATTATACTGCCT-
GACCAAGGAAAGC-39. The annealing reactions were carried
out at 65uC.
Immunofluorescence microscopy
Cord blood-derived ECFC were grown in gelatin 0.2% (Sigma-
Aldrich) coated Culture Slides BD Falcon
TM until they reached
confluence and stimulated with IFN-c (50 ng/ml) and TNF-a
(20 ng/ml)for16 h,unstimulated ECFCserveascontrol.Cellswere
fixed with 1% paraformaldehyde (PFA) solution for 10 min. To
prevent unspecific binding, ECFC were incubated for 1 h at room
temperature with PBS containing 3% BSA and 1% SVF. Then cells
were incubated with a goat anti-human CX3CL1 Ab, 5 mg/mL
(R&D Systems) for 30 min at 4uC, followed by an Alexa 488-
conjugated donkey anti-goat Ab, 2 mg/mL (Molecular Probes,
Invitrogen). Cells were fixed with 1% PFA for 10 min and further
incubated with a mouse anti-human CD31 Ab, 5 mg/mL
(Immunotech, BeckmanCoulter), followed byanAlexa546-coupled
goat anti-mouse Ab, 2 mg/mL (Molecular Probes, Invitrogen).
Furthermore, DAPI staining of cellnucleiwas performed for 10 min
at room temperature. Samples were analyzed by epi-fluorescence
microscopy on an inverted microscope Nikon Eclipse TE2000-U
with a Plan Fluor 20x/0.45 objective, images were acquired using
NIS elements AR software.
Expression plasmid constructs and ECFC transfection
The DNA fragment encoding membrane FKN was amplified
from FKN cDNA by PCR using following primers: 59NheI-
CX3CL1 primer (59-GCTAGCCAGCCATGGCTCCGATAT-
CTC-39); 39CX3CL1-NotI primer (59-GCGGCCGCTCACAC-
GGGCACCAGGA-39). FKN cDNA was cloned into mammalian
expression vector pCDNA3.1 (-) Hygro (Invitrogen, CergyPontoise,
France) using NheI-NotI restriction sites and into pIRES2EGFP
vector (Clontech, Ca, USA) using NheI-BamHI restriction sites.
AfteramplificationinE.colistrainTop10(Invitrogen),plasmidDNA
was purified using Endofree-Plasmid-Maxi-Preparation kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’s instructions.
For transfection, ECFC were suspended in nucleofector kit OLD
solution (Lonza, Saint Bauzire, France), mixed with 2 mgo f
pCDNA3.1 empty vector or pCDNA 3.1 coding for membrane
FKN and transfected using Amaxa Nucleofector apparatus II
(Lonza) and U-001 pulsing parameters. FKN expression was
evaluated by flow cytometry 24 h after nucleofection.
NK cell Adhesion assay
24 h prior to adhesion assay, cord blood-derived ECFC were
transfected with pCDNA3.1 (-) empty vector or with pCDNA3.1 (-)
encoding membrane FKN and plated onto 96-well plate at 10610
3
cells/well in EGM-2 medium and incubated for 24 h at 37uCi n5 %
CO2. Transfected cells were incubated for 1 h with CMFDA
labeled purified NK cells at 1:1 ratio. NK cell adhesion was
analyzed by epi-fluorescence microscopy on an inverted microscope
Nikon TE2000-U with a PlanFluor 4x/0.13 objective.The number
of ECFC-adherent NK cells/field was assessed using Image J 1.4
software cell counter. To assay the specific role of FKN in ECFC/
NK cell interactions, adhesion assays were also performed using
ECFC transfected with pIRES2-EGFP vector coding for both GFP
and FKN and transfected ECFC were incubated with 30 mg/ml of
FKN neutralizing antibody (R&D Systems) for 30 minutes at 37uC,
5% CO2. Then purified NK cells stained with 8 mg/ml DiD
Table 1. Univariate and multiple regression analysis explaining CD34
+ progenitor cells levels analyzed ex vivo in Kidney Transplant
Recipients.
CD34
+ cell count Univariate analysis Multivariate analysis
r Value Probability Beta coefficient Probability
% CD34
+ FKN
+ 20.2418 0.002 20.253 0.001
IS Treatment CSA/Aza 0.0307 0.6972
Age. yr 20.1629 0.0395 20.154 0.046
Gender (female) 20.0507 0.5241
BMI 0.189 0.0174 0.204 0.008
Uric acid mmol/l 0.1538 0.0749
Diabetes antecedents 20.1425 0.0695
Acute rejection antecedents 20.1585 0.0467 20.157 0.043
R2=0.122 pANOVA,0.0001
Variables that were significantly (p,0.05) associated with CD34
+ progenitor cell count or marginally significant (p,0.20) after univariate analysis were selected in the
multivariate model.
doi:10.1371/journal.pone.0026663.t001
Fractalkine Targets Progenitor Cell Lysis
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26663lipophilic tracer were incubated with FKN transfected ECFC for
1 h at effector: target ratio of 1:1. The number of ECFC-adherent
NK cells/field was assessed and ECFC-NK cell interactions were
imaged by resonance laser scanning confocal microscopy (SP5
Leica) using excitation wavelengths of 488 and 633 nm with 63x oil
immersion objective (N.A.=1.4).
Evaluation of ECFC lysis
CD34
+-derived ECFC were transfected with pCDNA3.1(-)
empty vector or with pCDNA3.1(-) coding for membrane FKN,
plated onto 96-well plate at 10610
3 cells/well in EGM-2 medium
andincubatedfor24 h at37uCin5%CO 2.Targetcells(transfected
ECFC) were labeled with 5 mM CellTracker
TM Green CMFDA
(Invitrogen) and incubated with PBMC at effector: target ratio of
50:1 for 4 h at 37uCi n5 %C O 2. After removing of medium, the
fluorescence of remaining adherent ECFC was measured using
PerSeptiveBiosystems Cytofluor4000 multi-plate cell reader (Ap-
plied Biosystems, Courtaboeuf, France). Assays were performed in
triplicate, and data were expressed as % of ECFC lysis:
%Lysis~
IFtargets{IF targetszeffectors ðÞ ½ 
IFtargets
|100:
Each well was also analyzed by epi-fluorescence microscopy on
an inverted microscope Nikon Eclipse TE2000-U with a Plan
Figure 5. FKN expression is induced on CD34
+ circulating progenitors by inflammatory cytokines and KTR sera. FKN expression was
assessed by flow cytometry after gating of CD34
+ cells within PBMC isolated from healthy donors after 20 h treatment with (A) sera from transplant
patients with high % of CD34
+FKN
+ cells or with (B) TNF-a (20 ng/ml) and IFN-c (50 ng/ml). Serum from healthy blood donors or control medium
served as controls. (C) FKN expression was also induced on CD34
+ cells gated within CD133-purified progenitors after a 20 h treatment with sera from
transplant patients.
doi:10.1371/journal.pone.0026663.g005
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elements AR software.
Microparticle release assay
24 h prior to test, CD34
+-derived ECFC were labeled with
Lipophilic Tracer DiD (Molecular Probes, Invitrogen) according to
the manufacturer’s instructions. Cells were transfected with
pCDNA3.1 empty vector or with pCDNA3.1 encoding membrane
FKN, seeded onto96-welland culturedinEGM-2mediumfor 24 hat
37uCi n5 %C O 2. PBMC effector cells were added at effector: target
r a t i oo f5 0 : 1a n di n c u b a t e dw i t ht a r g e tc e l l sf o r4ha n d2 4hi nR P M I
medium containing 5% SVF. After incubation, culture medium was
harvested, centrifuged 265minutesat 300 g and 10 minutesat 1500 g
to discard PBMC and cell debris and supernatants were collected for
flow cytometry analysis of ECFC-derived microparticles. Using 0.5
and 1.0 mm latex beads as gating parameters, EMP were defined as
particles #1 mm size and enumerated from the region corresponding
to DiD
+/Annexin
+ events on a Gallios cytometer (Beckman Coulter)
after adding 30 mL of counting beads at concentration of 960 beads/
mL( F l o w C o u n t
TMFluorospheres, BeckmanCoulter) to 30 mLo fe a c h
sample. Microparticles count was expressed as absolute numbers per
microliter of supernatant.
Flow cytometry analysis of FKN induction on CD34
+
circulating and ECFC progenitor cells
MembraneFKNexpressionwasanalyzedbyflowcytometryafter
gating on CD34
+ 7AAD
- viable circulating progenitors within
PBMC or CD133-purified cells. Briefly, CD133
+ cells were purified
from peripheralblood of healthy donors by magnetic cell separation
using the CD133 progenitor-cell isolation kit (Miltenyi Biotech
Bergisch-Gladbach, Germany). FKN induction was analyzed after
20 hstimulationofCD133
+cellsorPBMCwithStemSpanmedium
(Stem Cell Technologies), medium containing TNF-a (20 ng/ml)
and IFN-c (50 ng/ml) or 50% serum from transplant patients or
healthy blood donors. CD34
+-derived endothelial colony forming
cells (ECFC) were isolated from umbilical cord blood from healthy
volunteers and cultured as previously described [42]. For FKN
induction, cells at passage 2 to 4 were starved for 4 h in EBM-2
supplemented with 1% BSA and then stimulated with IFN-c
(50 ng/ml), TNF-a (20 ng/ml) or with a combination of IFN-
c+TNF-a for 16 h (mRNA analysis) or for 24 h (protein analysis).
After stimulation cells were trypsinized and stained with a mouse
anti-human FKN-PE or with mouse IgG1-PE (R&D Systems) and
analyzed on a FC500 cytometer (Beckman Coulter).
Patients and Ethics Statement
All patients and healthy volunteers who participated in this study
signed an informed consent. The clinical research protocol
supervised by Institut National de la Sante ´ et de la Recherche
Me ´dicale (Granted in 2008 under ref ID RCB 2008-A00604-51,
C07-17)has obtained approvalfromthefollowingethics committee:
Agence Franc ¸aise de se ´curite ´ sanitaire (Afssaps Ref B805-1860) and
Comite ´ de Protection des Personnes Sud Me ´diterrane ´e I, Marseille
France (CPP Sud Me ´diterrane ´e) to insure that procedures were
conducted in strict accordance with the Declaration of Helsinki
principles. From November 2008 to November 2010, 168 kidney
transplant recipients (KTR) followed in the transplant unit of
Centre de Nephrology et Transplantation Re ´nale, Ho ˆpital de la
Conception Marseilles, France were prospectively included in this
study after written informed consent. Median time post transplant
was 5.8 years post transplant (25–75 percentile range: 4.6–7.1).
Alternative immunosuppressive regimen used since transplant
was either Cyclosporine +Azathioprine (CSA/Aza, 53.6%) or
Tacrolimus + MycophenolateMofetil (TAC/MMF, 46.4). Median
BMI of transplanted patients was 25 (25–75 percentile range: 22.4–
27.2). Median recipient age was 54.2 (25–75 percentile range: 47–
61) and the analyzed cohort consisted of 107 male and 61 females.
Estimated Glomerular filtration rate (eGFR) was calculated using
the simplified MDRD equation (mean eGFR: 53.5, SD: 21.9).Graft
rejection episodes since transplant were detected in 11% of patients
foracuterejectionand23.4%forchronicrejection.Acontrolgroup
was composed of age- and gender-matched healthy volunteer blood
donors (n=58) without signs of renal failure. The control group was
composed of 31 men and 27 women, mean age 50.6 yrs (SD=9.16)
and eGFR: 98.9 ml/mn/1.73 m
2mean (SD=17.15).
Flow cytometry (flow cytometry) analysis of CD34
+ cell
count and FKN expression on CD34
+ cells in KTR
CD34
+ progenitors were analyzed within peripheral blood
mononuclear cells (PBMC) isolated from KTR and healthy donors
after density gradient centrifugation using lymphocyte separation
medium (Eurobio, Courtaboeuf, France). CD34
+ cells were
enumerated using Stem-Kit
TM (Beckman Coulter) as described
[8]. PBMC were stained with CD34-FITC, 7-AAD viability marker
(Beckman Coulter, Marseille, France) and FKN-PE antibodies
(R&D Systems, Minneapolis, MN, USA). Expression of FKN
(CX3CL1) was analyzed on a FC500 cytometer (Beckman Coulter)
using a two-dimensional side scatter-fluorescence dot plot after
gating on 7-AAD negative viable CD34
+ cells. Flow cytometry
analysis of NK cells within PBMC was performed as described [43].
Statistical analysis
Statistical analysis was performed using PASW Statistics version
17.0.2 (SPSS Inc., Chicago, IL, USA). Continuous variables were
tested for normal distribution with the Shapiro-Wilk normality test
and were expressed as mean 6 SD or as median with interquartile
range according to their distribution. Categorical variables were
reported as count or percentages. Association between continuous
variables was analyzed using Spearman’s Rank Correlation test.
The Pearson Chi-square test was used to check whether two
categorical variables are statistically associated. For continuous
variables, the medians for two groups were compared using non-
parametric Mann-Whitney test. The variables found to signifi-
cantly associate (p,0.05) with outcomes variables or marginally
significant (p,0.20) in the univariate analysis, or that had a clinical
relevance were selected in the multivariate model. Backward
multiple regression was used to construct models associating
CD34
+ cell count and %FKN
+CD34
+ with explanatory variables.
Acknowledgments
We thank Christine Calloustian and Josiane Casanova from the CIC for
their great participation as nurses dedicated to patient enrollment and
blood withdrawal. We acknowledge Aure ´lie Larosa for her contribution in
collection and editing of the clinical data, Mohamed Fatallah for
constructing the database and Alain Vazy for his help in managing receipt
and storage of blood samples and blood donation. We acknowledge Chloe ´
Dumoulin and Karim Fallague for their technical support. We also thank
Cecile Peltekian, Murielle Champeaux and members of the ‘‘COSSEC’’
INSERM for their support in management of the clinical protocol follow-
up. We thank the members of the AP-HM Direction de la Recherche for
their constant support of this translational research protocol.
Author Contributions
Conceived and designed the experiments: DT PP. Performed the
experiments: DT ED LL. Analyzed the data: DT PP AL. Contributed
reagents/materials/analysis tools: ND SR TL VM YB HVC SB SM.
Wrote the paper: DT PP FS SB FDG.
Fractalkine Targets Progenitor Cell Lysis
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26663References
1. Kirton JP, Xu Q (2010) Endothelial precursors in vascular repair. Microvascular
research 79: 193–199.
2. Zampetaki A, Kirton JP, Xu Q (2008) Vascular repair by endothelial progenitor
cells. Cardiovasc Res 78: 413–421.
3. Bompais H, Chagraoui J, Canron X, Crisan M, Liu XH, et al. (2004) Human
endothelial cells derived from circulating progenitors display specific functional
properties compared with mature vessel wall endothelial cells. Blood 103:
2577–2584.
4. Quyyumi AA, Waller EK, Murrow J, Esteves F, Galt J, et al. (2011) CD34(+) cell
infusion after ST elevation myocardial infarction is associated with improved
perfusion and is dose dependent. Am Heart J 161: 98–105.
5. Lavergne M, Vanneaux V, Delmau C, Gluckman E, Rodde-Astier I, et al.
(2011) Cord blood-circulating endothelial progenitors for treatment of vascular
diseases. Cell Prolif 44 Suppl 1: 44–47.
6. Tongers J, Losordo DW (2007) Frontiers in nephrology: the evolving therapeutic
applications of endothelial progenitor cells. J Am Soc Nephrol 18: 2843–2852.
7. Jie KE, Zaikova MA, Bergevoet MW, Westerweel PE, Rastmanesh M, et al.
(2010) Progenitor cells and vascular function are impaired in patients with
chronic kidney disease. Nephrol Dial Transplant 25: 1875–1882.
8. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, et al. (2009) Levels of
circulating endothelial progenitor cells are related to uremic toxins and vascular
injury in hemodialysis patients. J Thromb Haemost 7: 1576–1584.
9. de Groot K, Bahlmann FH, Bahlmann E, Menne J, Haller H, et al. (2005)
Kidney graft function determines endothelial progenitor cell number in renal
transplant recipients. Transplantation 79: 941–945.
10. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, van Es LA, Bruijn JA,
et al. (2001) Endothelial cell chimerism after renal transplantation and vascular
rejection. Lancet 357: 33–37.
11. Grimm PC, Nickerson P, Jeffery J, Savani RC, Gough J, et al. (2001) Neointimal
and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-
allograft rejection. N Engl J Med 345: 93–97.
12. Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, et al. (2009)
Low CD34+ cell count and metabolic syndrome synergistically increase the risk
of adverse outcomes. Atherosclerosis 207: 213–219.
13. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, et al. (2005) Circulating
endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:
999–1007.
14. Lau TT, Wang DA (2011) Stromal cell-derived factor-1 (SDF-1): homing factor
for engineered regenerative medicine. Expert Opin Biol Ther 11: 189–197.
15. Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, et al. (2008) Platelet-
derived stromal cell-derived factor-1 regulates adhesion and promotes
differentiation of human CD34+ cells to endothelial progenitor cells. Circulation
117: 206–215.
16. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, et al. (1997) A new class of
membrane-bound chemokine with a CX3C motif. Nature 385: 640–644.
17. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, et al. (2004)
Fractalkine in vascular biology: from basic research to clinical disease.
Arterioscler Thromb Vasc Biol 24: 34–40.
18. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, et al. (1997) Identification
and molecular characterization of fractalkine receptor CX3CR1, which
mediates both leukocyte migration and adhesion. Cell 91: 521–530.
19. Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, et al. (2000) Fractalkine-
mediated endothelial cell injury by NK cells. J Immunol 164: 4055–4062.
20. Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, et al. (2003)
Membrane-bound form of fractalkine induces IFN-gamma production by NK
cells. Eur J Immunol 33: 53–58.
21. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of
natural killer cells. Nat Immunol 9: 503–510.
22. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, et al. NK cell
transcripts and NK cells in kidney biopsies from patients with donor-specific
antibodies: evidence for NK cell involvement in antibody-mediated rejection.
Am J Transplant 10: 1812–1822.
23. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, et al. (2006) The
changing role of natural killer cells in solid organ rejection and tolerance.
Transplantation 81: 811–817.
24. Romo N, Fito M, Guma M, Sala J, Garcia C, et al. (2011) Association of
Atherosclerosis With Expression of the LILRB1 Receptor By Human NK and
T-Cells Supports the Infectious Burden Hypothesis. Arterioscler Thromb Vasc
Biol 31: 2314–2321.
25. Bobryshev YV, Lord RS (2005) Identification of natural killer cells in human
atherosclerotic plaque. Atherosclerosis 180: 423–427.
26. D’Haese JG, Demir IE, Friess H, Ceyhan GO (2010) Fractalkine/CX3CR1:
why a single chemokine-receptor duo bears a major and unique therapeutic
potential. Expert Opin Ther Targets 14: 207–219.
27. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, et al. (2001)
Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft
rejection. J Clin Invest 108: 679–688.
28. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, et al. (2000) A
role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection.
J Immunol 165: 6067–6072.
29. Shimizu A, Colvin RB, Yamanaka N (2000) Rejection of peritubular capillaries
in renal allo- and xeno-graft. Clin Transplant 14 Suppl 3: 6–14.
30. Hoffmann U, Bergler T, Segerer S, Rummele P, Kruger B, et al. (2010) Impact
of chemokine receptor CX3CR1 in human renal allograft rejection. Transpl
Immunol 23: 204–208.
31. Furuichi K, Gao JL, Murphy PM (2006) Chemokine receptor CX3CR1
regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol
169: 372–387.
32. Shimizu K, Furuichi K, Sakai N, Kitagawa K, Matsushima K, et al. (2011)
Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis
in the kidney. Hypertens Res 34: 747–752.
33. Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, et al. (2007) Activation of
plasminogen into plasmin at the surface of endothelial microparticles: a
mechanism that modulates angiogenic properties of endothelial progenitor cells
in vitro. Blood 110: 2432–2439.
34. Dignat-George F, Boulanger CM (2011) The many faces of endothelial
microparticles. Arterioscler Thromb Vasc Biol 31: 27–33.
35. Kutukculer N, Shenton BK, Clark K, Rigg KM, Forsythe JL, et al. (1995) Renal
allograft rejection: the temporal relationship and predictive value of plasma TNF
(alpha and beta), IFN-gamma and soluble ICAM-1. Transpl Int 8: 45–50.
36. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, et al. (2006)
Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur
Heart J 27: 2247–2255.
37. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, et al. (2005)
Reduced number of circulating endothelial progenitor cells predicts future
cardiovascular events: proof of concept for the clinical importance of
endogenous vascular repair. Circulation 111: 2981–2987.
38. Osto E, Castellani C, Fadini GP, Baesso I, Gambino A, et al. (2011) Impaired
endothelial progenitor cell recruitment may contribute to heart transplant
microvasculopathy. J Heart Lung Transplant 30: 70–76.
39. Whitman SC, Rateri DL, Szilvassy SJ, Yokoyama W, Daugherty A (2004)
Depletion of natural killer cell function decreases atherosclerosis in low-density
lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol 24: 1049–1054.
40. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, et al. (2008)
Tolerance and chimerism after renal and hematopoietic-cell transplantation.
N Engl J Med 358: 362–368.
41. Farris AB, Taheri D, Kawai T, Fazlollahi L, Wong W, et al. (2011) Acute renal
endothelial injury during marrow recovery in a cohort of combined kidney and
bone marrow allografts. Am J Transplant 11: 1464–1477.
42. Delorme B, Basire A, Gentile C, Sabatier F, Monsonis F, et al. (2005) Presence
of endothelial progenitor cells, distinct from mature endothelial cells, within
human CD146+ blood cells. Thromb Haemost 94: 1270–1279.
43. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, et al. (2007) Distinctive
NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in
HIV-exposed uninfected individuals. Blood 109: 4296–4305.
Fractalkine Targets Progenitor Cell Lysis
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e26663